Therapeutic targeting of the DNA damage response in prostate cancer

Catherine H. Marshall; Emmanuel S. Antonarakis

doi:10.1097/CCO.0000000000000617

Therapeutic targeting of the DNA damage response in prostate cancer

Catherine H. Marshall, Emmanuel S. Antonarakis

Research output: Contribution to journal › Review article › peer-review

12 Scopus citations

Abstract

Purpose of reviewThe present article highlights the most common DNA repair gene mutations, using specific examples of individual genes or gene classes, and reviews the epidemiology and treatment implications for each one [with particular emphasis on poly-ADP-ribose polymerase (PARP) inhibition and PD-1 blockade].Recent findingsGenetic and genomic testing have an increasingly important role in the oncology clinic. For patients with prostate cancer, germline genetic testing is now recommended for all men with high-risk and metastatic disease, and somatic multigene tumor testing is recommended for men with metastatic castration-resistant disease. The most common mutations that are present in men with advanced prostate cancer are in genes coordinating DNA repair and the DNA damage response.SummaryAlthough much of what is discussed currently remains investigational, it is clear that genomically-targeted treatments will become increasingly important for patients with prostate cancer in the near future and beyond.

Original language	English (US)
Pages (from-to)	216-222
Number of pages	7
Journal	Current Opinion in Oncology
Volume	32
Issue number	3
DOIs	https://doi.org/10.1097/CCO.0000000000000617
State	Published - May 1 2020
Externally published	Yes

Bibliographical note

Funding Information:
C.H.M. has received research funding via the Conquer Cancer Foundation from Bristol Myers-Squibb and travel support from Dava Oncology; and also serves as a paid consultant to McGraw-Hill publishing company. E.S.A. is a paid consultant/advisor to Janssen, Astellas, Sanofi, Dendreon, Pfizer, Amgen, AstraZeneca, Bristol-Myers Squibb, Clovis, and Merck; he has received research funding to his institution from Janssen, Johnson & Johnson, Sanofi, Dendreon, Genentech, Novartis, Tokai, Bristol Myers-Squibb, AstraZeneca, Clovis, and Merck; and he is the co-inventor of a biomarker technology that has been licensed to Qiagen.

Funding Information:
C.H.M. and E.S.A. are partially funded by NIH grant P30CA006973.

Publisher Copyright:
© 2020 Lippincott Williams and Wilkins. All rights reserved.

Keywords

ATM
BRCA1/2
DNA repair
genomics
prostate cancer

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1097/CCO.0000000000000617

Find It

Find It at U of M Libraries

Cite this

@article{c89ff2390a04458699c8fb17a03ebf4c,

title = "Therapeutic targeting of the DNA damage response in prostate cancer",

abstract = "Purpose of reviewThe present article highlights the most common DNA repair gene mutations, using specific examples of individual genes or gene classes, and reviews the epidemiology and treatment implications for each one [with particular emphasis on poly-ADP-ribose polymerase (PARP) inhibition and PD-1 blockade].Recent findingsGenetic and genomic testing have an increasingly important role in the oncology clinic. For patients with prostate cancer, germline genetic testing is now recommended for all men with high-risk and metastatic disease, and somatic multigene tumor testing is recommended for men with metastatic castration-resistant disease. The most common mutations that are present in men with advanced prostate cancer are in genes coordinating DNA repair and the DNA damage response.SummaryAlthough much of what is discussed currently remains investigational, it is clear that genomically-targeted treatments will become increasingly important for patients with prostate cancer in the near future and beyond.",

keywords = "ATM, BRCA1/2, DNA repair, genomics, prostate cancer",

author = "Marshall, {Catherine H.} and Antonarakis, {Emmanuel S.}",

note = "Funding Information: C.H.M. has received research funding via the Conquer Cancer Foundation from Bristol Myers-Squibb and travel support from Dava Oncology; and also serves as a paid consultant to McGraw-Hill publishing company. E.S.A. is a paid consultant/advisor to Janssen, Astellas, Sanofi, Dendreon, Pfizer, Amgen, AstraZeneca, Bristol-Myers Squibb, Clovis, and Merck; he has received research funding to his institution from Janssen, Johnson & Johnson, Sanofi, Dendreon, Genentech, Novartis, Tokai, Bristol Myers-Squibb, AstraZeneca, Clovis, and Merck; and he is the co-inventor of a biomarker technology that has been licensed to Qiagen. Funding Information: C.H.M. and E.S.A. are partially funded by NIH grant P30CA006973. Publisher Copyright: {\textcopyright} 2020 Lippincott Williams and Wilkins. All rights reserved.",

year = "2020",

month = may,

day = "1",

doi = "10.1097/CCO.0000000000000617",

language = "English (US)",

volume = "32",

pages = "216--222",

journal = "Current Opinion in Oncology",

issn = "1040-8746",

publisher = "Lippincott Williams and Wilkins",

number = "3",

}

TY - JOUR

T1 - Therapeutic targeting of the DNA damage response in prostate cancer

AU - Marshall, Catherine H.

AU - Antonarakis, Emmanuel S.

N1 - Funding Information: C.H.M. has received research funding via the Conquer Cancer Foundation from Bristol Myers-Squibb and travel support from Dava Oncology; and also serves as a paid consultant to McGraw-Hill publishing company. E.S.A. is a paid consultant/advisor to Janssen, Astellas, Sanofi, Dendreon, Pfizer, Amgen, AstraZeneca, Bristol-Myers Squibb, Clovis, and Merck; he has received research funding to his institution from Janssen, Johnson & Johnson, Sanofi, Dendreon, Genentech, Novartis, Tokai, Bristol Myers-Squibb, AstraZeneca, Clovis, and Merck; and he is the co-inventor of a biomarker technology that has been licensed to Qiagen. Funding Information: C.H.M. and E.S.A. are partially funded by NIH grant P30CA006973. Publisher Copyright: © 2020 Lippincott Williams and Wilkins. All rights reserved.

PY - 2020/5/1

Y1 - 2020/5/1

N2 - Purpose of reviewThe present article highlights the most common DNA repair gene mutations, using specific examples of individual genes or gene classes, and reviews the epidemiology and treatment implications for each one [with particular emphasis on poly-ADP-ribose polymerase (PARP) inhibition and PD-1 blockade].Recent findingsGenetic and genomic testing have an increasingly important role in the oncology clinic. For patients with prostate cancer, germline genetic testing is now recommended for all men with high-risk and metastatic disease, and somatic multigene tumor testing is recommended for men with metastatic castration-resistant disease. The most common mutations that are present in men with advanced prostate cancer are in genes coordinating DNA repair and the DNA damage response.SummaryAlthough much of what is discussed currently remains investigational, it is clear that genomically-targeted treatments will become increasingly important for patients with prostate cancer in the near future and beyond.

AB - Purpose of reviewThe present article highlights the most common DNA repair gene mutations, using specific examples of individual genes or gene classes, and reviews the epidemiology and treatment implications for each one [with particular emphasis on poly-ADP-ribose polymerase (PARP) inhibition and PD-1 blockade].Recent findingsGenetic and genomic testing have an increasingly important role in the oncology clinic. For patients with prostate cancer, germline genetic testing is now recommended for all men with high-risk and metastatic disease, and somatic multigene tumor testing is recommended for men with metastatic castration-resistant disease. The most common mutations that are present in men with advanced prostate cancer are in genes coordinating DNA repair and the DNA damage response.SummaryAlthough much of what is discussed currently remains investigational, it is clear that genomically-targeted treatments will become increasingly important for patients with prostate cancer in the near future and beyond.

KW - ATM

KW - BRCA1/2

KW - DNA repair

KW - genomics

KW - prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85083042253&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85083042253&partnerID=8YFLogxK

U2 - 10.1097/CCO.0000000000000617

DO - 10.1097/CCO.0000000000000617

M3 - Review article

C2 - 32168038

AN - SCOPUS:85083042253

SN - 1040-8746

VL - 32

SP - 216

EP - 222

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

IS - 3

ER -

Therapeutic targeting of the DNA damage response in prostate cancer

Abstract

Bibliographical note

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this